MUC1 Activity Enhancement for Pluripotent Stem Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing pluripotency in somatic cells are inefficient, leading to low rates of reprogramming, which makes therapeutic uses of induced pluripotent stem cells impractical due to issues with viral vector integration and undesirable side effects from oncogenic genes like c-Myc and Klf4.
Innovation Solution
Contacting cells with biological or chemical species that increase MUC1* activity, such as MUC1 ligands like NM23 or small molecules that enhance MUC1 transcription or cleavage, to induce or maintain pluripotency, potentially replacing or complementing existing pluripotency-inducing genes like OCT4, SOX2, NANOG, and c-Myc.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple viral vectors are used to express transcription factors for inducing pluripotency, then reprogramming can be achieved, but the risk of oncogenicity increases due to multiple integration events
Solution Approach 1:
The patent extracts and removes the harmful integrating viral vectors from the reprogramming system. Instead of using viral vectors that integrate into the genome, the invention employs non-integrating methods such as transient transfection of plasmid DNA or use of episomal vectors, thereby eliminating the risk of insertional mutagenesis and oncogenicity while maintaining reprogramming capability
Solution Approach 2:
The patent employs transient, non-persistent delivery methods for transcription factors that do not require permanent genomic integration. The reprogramming factors are delivered temporarily through transfection or transient expression systems, allowing the cells to be reprogrammed without long-term presence of foreign genetic material, thus reducing safety risks
2Productivity
If oncogenic genes like c-Myc and Klf4 are used to induce pluripotency, then reprogramming efficiency is improved, but undesirable side effects such as cancer and dysplasia occur
Solution Approach 1:
The patent replaces harmful oncogenic transcription factors with small molecule compounds that can induce similar or enhanced reprogramming effects without the carcinogenic side effects. Small molecules such as HDAC inhibitors, GSK3 inhibitors, and other chemical compounds are used to activate endogenous pluripotency networks, converting the harmful approach of using oncogenes into a safe chemical biology approach
Solution Approach 2:
The patent changes the nature of the reprogramming inducers from genetic factors (transcription factors) to chemical factors (small molecules). This parameter change allows for precise temporal and dosage control of reprogramming, enables reversible effects, and eliminates the risk of uncontrolled oncogenic activity while maintaining or improving reprogramming efficiency
3Object-affected harmful factors
If single vector systems, excisable vectors, or non-integrating vectors are used to reduce oncogenicity, then safety is improved, but reprogramming efficiency becomes extremely low
Solution Approach 1:
The patent combines multiple small molecule compounds with synergistic effects to achieve high reprogramming efficiency. By using combinations of small molecules that target different pathways (e.g., HDAC inhibition combined with GSK3 inhibition, or combining pluripotency-inducing small molecules with differentiation blockade agents), the invention achieves efficient reprogramming while maintaining safety
Solution Approach 2:
The patent employs composite reprogramming systems that integrate multiple small molecule compounds, potentially combined with non-integrating genetic elements or protein delivery, to create a multifaceted reprogramming approach. This composite strategy leverages the complementary mechanisms of different agents to achieve high efficiency without the drawbacks of viral integration or oncogene use
Data Source
AI summary
The present application describes a method for inducing or maintaining pluripotency in a cell by contacting the cell with a biological or chemical species that increases MUC1* activity.